Becoming the “Customer of Choice”: A Strategic Imperative for CDMOs and API Specialists

In today’s rapidly evolving pharmaceutical ecosystem, the relationship between drug sponsors and their outsourced partners is more strategic than ever before. For companies engaged in active pharmaceutical ingredient development and manufacturing through a contract development and manufacturing organization model, the notion of being the “customer of choice” is no longer a luxuryEM_DASHit is a key differentiator.

What does “customer of choice” mean?

A useful definition from Gartner describes a “customer of choice” as “one that receives priority treatment when accessing the services or products of a provider.”

In the CDMO/API space, this translates into a sponsoring company being viewed by its CDMO partner as a preferred clientEM_DASHwith advantages such as:

• preferential access to capacity and materials, especially in constrained supply-chain environments;
• closer, earlier involvement in planning, innovation, and risk-sharing;
• improved transparency and collaboration, rather than purely transactional vendor-customer relationships.

This mindset shifts from buyer treating the CDMO as a commodity vendor, to the CDMO treating the buyer as a valued partnerEM_DASHmarks a strong evolution in value-chain thinking.

The CDMO industry has changed dramatically in recent years. APIs have become more complex, regulatory pressures higher, and supply-chain risk more visible. For example:

• The API/bulk drug market remains a strong growth area, and CDMOs with broad capabilities (from development through commercial manufacturing) lead to a premium.
• Sponsors increasingly seek CDMOs that can span early-stage development, scale-up, and commercial supplyEM_DASHthus reducing hand-offs and reducing risk.
• The supply-chain disruption triggered by recent global challenges has made reliable partnerships and prioritization of trusted clients a real strategic asset.

In such a context, a sponsoring company that positions itself as a customer of choice offers its CDMO partner more than just the next contract: it offers long-term strategic alignment, shared risk, and enhanced mutual benefit. This in turn can yield benefits such as priority scheduling, preferential capacity, more innovation input, and in some cases, more favorable commercial terms.

Based on recent industry commentary and research, for a company to be seen as a customer of choice by its CDMO/API partner, the following attributes are key:

• Early engagement and transparency

Involve the CDMO earlyEM_DASHin pre-planning, molecule selection, scale-up strategy. This signals that you see the partner as a co-creator rather than a task-executor.

• Respect for mutual constraints and partnership mindset

Recognize that your CDMO partner is running a high-complexity business with capacity, regulatory, and investment constraints. Acknowledging this fosters trust. Research indicates that CDMOs value customers who “respect their need to be profitable” and engage collaboratively.

• Consistency, reliability and predictability

Strong customers of choice deliver clear forecasts, timely decision-making, minimal last-minute changes, and high communication quality. This helps the CDMO optimize capacity and resource allocation.

• Innovation orientation and value creation

Rather than simply focusing on lowest cost, a true customer of choice brings innovation demand, joint development, and opportunities for co-investment in new processes, enabling the CDMO to invest in advanced capabilities (e.g., HPAPI handling, continuous manufacturing).

• Mutual supply-chain visibility and resilience

With supply chains under stress globally, companies that provide high-quality data, collaborate on risk mitigation and engage in transparent supply-chain practices are more likely to receive priority from CDMOs. For example, a study noted that suppliers were “24 % more likely to go the extra mile for a customer of choice”.

At the interface of business development and innovation, the value of being a customer of choice can be translated into real competitive advantage:

Faster time-to-market: With preferred access to capacity and faster decision-making, projects can move more smoothly from development into commercial manufacturing.

Stronger risk mitigation: When your CDMO gives priority to your molecule, you reduce the chance of delays or being bumped by competing work.

Better innovation pipeline: A partner-mindset allows your CDMO to invest in new technologies and share their insights, which can support your differentiation as a drug sponsor.

Enhanced strategic positioning: For your company to win and retain projects with innovative value, demonstrating that you are a preferred, high-value partner for your CDMO strengthens your credibility.

Value beyond cost: In a complex API/CDMO environment, cost is only one dimension. Quality, agility, innovation and collaborative mindset are increasingly criticalEM_DASHand being a customer of choice is a way to signal that you embrace that broader value equation.

In conclusion, in a CDMO/API landscape characterized by complexity, supply-chain risk and technological evolution, being a customer of choice is more than a badgeEM_DASHit is a strategic capability. For a company like yours, led in business development and innovation, embracing the mindset and behaviors of a preferred client puts you ahead of the curve: enabling faster, more reliable collaborations, deeper innovation, and stronger strategic alignment with your CDMO partner. The transition from “just another outsourcing contract” to “strategic partnership” is what will differentiate the leaders in this space.

By investing in the relationship, sharing innovation, and acting with transparency and partnership spirit, you position your company not just as a buyer of services, but as a valued collaboratorEM_DASHa true customer of choice.

References and notes

• DCAT Value Chain Insights What Makes A Customer of Choice: Are Pharma Companies  and  Suppliers Aligned?  https://www.dcatvci.org/features/what-makes-a-customer-of-choice-are-pharma-companies-suppliers-aligned/
• PharmaVentures – Value Creation in the CDMO Market, March 2023.  PV-White-Paper-CDMO.pdf
• DrugPatentWatch – “Key Factors for Choosing the Right CDMO”, July 16 2025. How to Pick the Right CDMO: The Definitive Playbook for Pharma IP Teams, Portfolio Managers, and R&D Leads – DrugPatentWatch – Transform Data into Market Domination
• Global Trade Magazine: “How Pharmaceutical Brands can be Resilient” (Costas Xyloyiannis), Nov 6 2023.  Global Trade Magazine How Pharmaceutical Brands can be Resilient: Let’s approach Supply Chain Resilience Holistically – Global Trade Magazine